Biomedical Engineering Reference
In-Depth Information
10. Long SB, Campbell EB, Mackinnon R (2005) Crystal structure of a mammalian voltage-
dependent Shaker family K+ channel. Science 309:897-903
11. Yellen G (1998) The moving parts of voltage-gated ion channels. Q Rev Biophys
31:239-295
12. MacKinnon R (2004) Potassium channels and the atomic basis of selective ion conduction
(Nobel Lecture). Angew Chem Int Ed Engl 43:4265-4277
13. Jiang Y, Lee A, Chen J et al (2002) The open pore conformation of potassium channels.
Nature 417:523-526
14. Long SB, Campbell EB, Mackinnon R (2005) Voltage sensor of Kv1.2: structural basis of
electromechanical coupling. Science 309:903-908
15. Hackos DH, Chang TH, Swartz KJ (2002) Scanning the intracellular S6 activation gate in the
shaker K+ channel. J Gen Physiol 119:521-532
16. Lu Z, Klem AM, Ramu Y (2002) Coupling between voltage sensors and activation gate in
voltage-gated K+ channels. J Gen Physiol 120:663-676
17. Hondeghem LM (2000) Classification of antiarrhythmic agents and the two laws of pharma-
cology. Cardiovasc Res 45:57-60
18. Sanguinetti MC, Jiang C, Curran ME et al (1995) A mechanistic link between an inherited
and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell
81:299-307
19. Stroobandt R, Stiels B, Hoebrechts R (1997) Propafenone for conversion and prophylaxis of
atrial fibrillation. Propafenone Atrial Fibrillation Trial
Investigators. Am J Cardiol
79:418-423
20. Aliot E, Denjoy I (1996) Comparison of the safety and efficacy of flecainide versus
propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter.
The Flecainide AF French Study Group. Am J Cardiol 77:66A-71A
21. Naccarelli GV, Wolbrette DL, Khan M et al (2003) Old and new antiarrhythmic drugs for
converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and
results of trials. Am J Cardiol 91:15D-26D
22. Lombardi F, Borggrefe M, Ruzyllo W et al (2006) Azimilide vs. placebo and sotalol for
persistent atrial fibrillation: the A-COMET-II (Azimilide-CardiOversion MaintEnance Trial-
II) trial. Eur Heart J 27:2224-2231
23. Hancox JC, McPate MJ, El Harchi A et al (2008) The hERG potassium channel and hERG
screening for drug-induced torsades de pointes. Pharmacol Ther 119:118-132
24. Khanderia U, Wagner D, Walker PC et al (2008) Amiodarone for atrial fibrillation following
cardiac surgery: development of clinical practice guidelines at a university hospital. Clin
Cardiol 31(1):6-10
25. Touboul P, Brugada J, Capucci A et al (2003) Dronedarone for prevention of atrial fibrilla-
tion: a dose-ranging study. Eur Heart J 24:1481-1487
26. Wang Z, Fermini B, Nattel S (1993) Sustained depolarization-induced outward current in
human atrial myocytes. Evidence for a novel delayed rectifier K+ current similar to Kv1.5
cloned channel currents. Circ Res 73:1061-1076
27. Li GR, Feng J, Wang Z et al (1996) Adrenergic modulation of ultrarapid delayed rectifier K+
current in human atrial myocytes. Circ Res 78:903-915
28. Van Wagoner DR, Pond AL, McCarthy PM et al (1997) Outward K+ current densities and
Kv1.5 expression are reduced in chronic human atrial fibrillation. Circ Res 80:772-781
29. Lip GY, Tse HF (2007) Management of atrial fibrillation. Lancet 370:604-618
30. Kaye DM, Krum H (2007) Drug discovery for heart failure: a new era or the end of the
pipeline? Nat Rev Drug Discov 6:127-139
31. Conway E, Musco S, Kowey PR (2008) New horizons in antiarrhythmic therapy: will novel
agents overcome current deficits? Am J Cardiol 102:12H-19H
32. Li GR, Feng J, Yue L et al (1996) Evidence for two components of delayed rectifier K+
current in human ventricular myocytes. Circ Res 78:689-696
